Portland, ORNCT07405086Now EnrollingIRB Ready

Advanced Biliary Tract Carcinoma Clinical Trial in Portland, OR

Access cutting-edge advanced biliary tract carcinoma treatment through this clinical trial at a research site in Portland. Study-provided care at no cost to qualified participants.

Sponsored by OHSU Knight Cancer Institute

Quick Self-Assessment

See if you qualify for this Portland location

Preparing your pre-screening questions…

Expert Care in Portland

Access advanced biliary tract carcinoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related advanced biliary tract carcinoma treatment provided free

Apply for This Portland Location

Check if you qualify for this advanced biliary tract carcinoma clinical trial in Portland, OR

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Portland

    Convenient for OR residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Portland site if eligible
  4. 4Begin participation

About This Advanced Biliary Tract Carcinoma Study in Portland

This phase IV trial is evaluating whether morning versus afternoon administration of standard of care immunotherapy impacts its effectiveness in treating patients with solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Immunotherapy with monoclonal antibodies may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Circadian rhythm refers to the internal biological clock in which various processes in the body, including immune cell activity, are controlled by the time of day. Exactly how this works is not fully understood, and the researchers want to see if circadian rhythm control of the immune system can influence response to immunotherapy based on whether it is given in the morning (before 11:00 am) or afternoon (12:00pm). The time of day that immunotherapy is given (morning versus afternoon) may impact the effectiveness in treating patients with advanced or metastatic solid tumors.

Sponsor: OHSU Knight Cancer Institute

Who Can Participate

Inclusion Criteria

Must provide written informed consent before any study-specific procedures or interventions are performed
Aged ≥ 18 years
Histologically confirmed advanced/metastatic solid tumor as follows:
Non small cell lung cancer (NSCLC) (driver-negative, immune checkpoint inhibitor \[ICI\]-eligible)
Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) (platinum-eligible),
Renal cell carcinoma (RCC)
Biliary-tract cancer (BTC)
Hepatocellular carcinoma (HCC)
Planned to receive a Food and Drug Administration (FDA)-approved immune check point inhibitor (e.g., anti-PD-1, anti-PD-L1, anti-CTLA4) regimen for the treatment of their malignancy
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

Exclusion Criteria

Prior ICI-based regimen for treatment of cancer
Current or prior use of immunosuppressive medication within 28 days before planned standard-of-care immunotherapy infusion, with the exception of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses not exceeding 10 mg/day of prednisone (or equivalent corticosteroid)
Uncontrolled autoimmune disease requiring immunosuppression
Active, uncontrolled central nervous system (CNS) metastases

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Portland?

Yes, this clinical trial (NCT07405086) has an active research site in Portland, OR that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Advanced Biliary Tract Carcinoma Treatment Options in Portland, OR

If you're searching for advanced biliary tract carcinoma treatment options in Portland, OR, this clinical trial (NCT07405086) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Portland research site is actively enrolling participants for this clinical trial. You'll receive care from experienced advanced biliary tract carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all advanced biliary tract carcinoma clinical trials near you to find additional studies recruiting in your area.

More Alzheimers Disease Trials in Portland, OR

See all alzheimers disease clinical trials recruiting in Portland — not just this study.

Browse Alzheimers Disease Trials in Portland

Ready to Join in Portland?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Portland, OR